Literature DB >> 19688966

Multidisciplinary approach to the treatment of bone metastases: Osteo-Oncology Center, a new organizational model.

Toni Ibrahim1, Emanuela Flamini, Laura Fabbri, Patrizia Serra, Laura Mercatali, Rossana Ricci, Emanuele Sacanna, Maria Cristina Falasconi, Roberto Casadei, Riccardo Galassi, Massimo Giannini, Oscar Bazzocchi, Filippo Calzolari, Roberta Nunziatini, Michele Gaudio, Marco Maltoni, Dino Amadori.   

Abstract

AIMS AND
BACKGROUND: Bone metastases are responsible for high morbidity in cancer patients. The frequency of pain and other serious complications associated with such metastases depends on the site and type of lesions and preventive therapy. The present paper aims to inform the scientific community about a new organizational health care model specifically designed for patients with bone metastases, in the hope of stimulating the creation of similar initiatives whose goals are to decrease the high morbidity of this pathology, reduce the frequency of complications, limit psychophysical distress of patients, and improve quality of life.
METHODS: In January 2005, an Osteo-Oncology Center was opened in our institute to provide multidisciplinary care (19 specialists involved) for patients with bone metastases, to train physicians, and to conduct research in the field.
RESULTS: In its first three years of activity, 601 multidisciplinary team consultations were made and a total of 425 patients were seen. The most frequent primary tumor site was the lung in males and the breast in females. Upon presentation at the Center, 79% of patients reported experiencing a level of pain (median pain intensity, 3.69) that interfered with normal daily activities. An anonymous questionnaire was also completed on the quality of the service provided: 75% of patients were very satisfied, 23% were satisfied, 1% responded "I don't know", and only 1% expressed dissatisfaction.
CONCLUSIONS: Our preliminary results confirm the usefulness of a multidisciplinary center for the management of patients with bone metastases, especially in terms of decreasing psychophysical suffering.

Entities:  

Mesh:

Year:  2009        PMID: 19688966     DOI: 10.1177/030089160909500304

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  20 in total

1.  Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma.

Authors:  Roberto Iacovelli; Daniele Santini; Mimma Rizzo; Alessandra Felici; Matteo Santoni; Elena Verzoni; Cristina Masini; Francesco Massari; Nicola Calvani; Alessandra Mosca; Giuseppe Procopio
Journal:  Can Urol Assoc J       Date:  2015 Jul-Aug       Impact factor: 1.862

Review 2.  Multidisciplinary care of breast cancer patients: a scoping review of multidisciplinary styles, processes, and outcomes.

Authors:  J Shao; M Rodrigues; A L Corter; N N Baxter
Journal:  Curr Oncol       Date:  2019-06-01       Impact factor: 3.677

3.  RANKL: A promising circulating marker for bone metastasis response.

Authors:  Toni Ibrahim; Marianna Ricci; Emanuela Scarpi; Alberto Bongiovanni; Rossana Ricci; Nada Riva; Chiara Liverani; Alessandro De Vita; Federico La Manna; Devil Oboldi; Patrizia Serra; Flavia Foca; Lorenzo Cecconetto; Dino Amadori; Laura Mercatali
Journal:  Oncol Lett       Date:  2016-08-08       Impact factor: 2.967

4.  Silibinin inhibits prostate cancer cells- and RANKL-induced osteoclastogenesis by targeting NFATc1, NF-κB, and AP-1 activation in RAW264.7 cells.

Authors:  Chandagirikoppal V Kavitha; Gagan Deep; Subhash C Gangar; Anil K Jain; Chapla Agarwal; Rajesh Agarwal
Journal:  Mol Carcinog       Date:  2012-10-31       Impact factor: 4.784

Review 5.  Bone and cancer: the osteoncology.

Authors:  Toni Ibrahim; Laura Mercatali; Dino Amadori
Journal:  Clin Cases Miner Bone Metab       Date:  2013-05

Review 6.  Reader's digest of the pathophysiology of bone metastases.

Authors:  Reinhard Gruber
Journal:  Wien Med Wochenschr       Date:  2012-07-14

7.  Impact of a Specialized Outpatient Clinic on Bone Metastasis and Its Burden on Spine Surgeons.

Authors:  Hiroyuki Tsuchie; Naohisa Miyakoshi; Michio Hongo; Hiroyuki Nagasawa; Yuji Kasukawa; Daisuke Kudo; Ryota Kimura
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

Review 8.  Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology.

Authors:  H Shibata; S Kato; I Sekine; K Abe; N Araki; H Iguchi; T Izumi; Y Inaba; I Osaka; S Kato; A Kawai; S Kinuya; M Kodaira; E Kobayashi; T Kobayashi; J Sato; N Shinohara; S Takahashi; Y Takamatsu; K Takayama; K Takayama; U Tateishi; H Nagakura; M Hosaka; H Morioka; T Moriya; T Yuasa; T Yurikusa; K Yomiya; M Yoshida
Journal:  ESMO Open       Date:  2016-03-16

9.  Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid.

Authors:  Toni Ibrahim; Laura Mercatali; Emanuele Sacanna; Anna Tesei; Silvia Carloni; Paola Ulivi; Chiara Liverani; Francesco Fabbri; Michele Zanoni; Wainer Zoli; Dino Amadori
Journal:  Cancer Cell Int       Date:  2012-11-22       Impact factor: 5.722

10.  A new emergency in oncology: Bone metastases in breast cancer patients (Review).

Authors:  Toni Ibrahim; Laura Mercatali; Dino Amadori
Journal:  Oncol Lett       Date:  2013-06-04       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.